中文版 | English
Title

噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌肺部感染的病例报道

Alternative Title
A case report of phage therapy against lung infection caused by Carbapenem-resistant Acinetobacter baumannii and Carbapenem-resistant Pseudomonas aeruginosa
Author
Publication Years
2022
DOI
Source Title
ISSN
2096-2738
Volume7Issue:2Pages:71-75
Abstract
82岁男性患者,因反复肺部感染半年入院.患者既往有阿尔茨海默病史.本次入院前多次痰培养为耐碳青霉烯鲍曼不动杆菌和耐碳青霉烯铜绿假单胞菌,使用包括替加环素在内的多种抗生素,患者痰细菌培养未转阴、肺部感染未改善.入院后予鲍曼不动杆菌噬菌体加铜绿假单胞菌噬菌体鸡尾酒疗法,每天2次雾化吸入,疗程分别为10d和19d;联合静脉滴注替加环素、哌拉西林他唑巴坦和阿米卡星.患者耐受良好,痰培养未见鲍曼不动杆菌生长,痰中铜绿假单胞菌荷菌量减少,临床症状和胸部X线片提示肺部感染明显好转.
Keywords
URL[Source Record]
Language
Chinese
SUSTech Authorship
First
Data Source
WanFang
WanFangID
xfcrbdzzz202202015
Citation statistics
Cited Times [WOS]:0
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/401890
DepartmentThe Third People's Hospital of Shenzhen
Affiliation
1.深圳市第三人民医院呼吸内科,国家感染性疾病临床医学研究中心,南方科技大学第二附属医院,广东 深圳 518112
2.深圳合成基因组学重点实验室,广东省合成基因组学重点实验室,中国科学院定量工程生物学重点实验室,深圳合成生物学研究所,中国科学院深圳先进技术研究院,广东 深圳 518055
First Author AffilicationThe Third People's Hospital of Shenzhen
First Author's First AffilicationThe Third People's Hospital of Shenzhen
Recommended Citation
GB/T 7714
陈培芬,孔英君,文思,等. 噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌肺部感染的病例报道[J]. 新发传染病电子杂志,2022,7(2):71-75.
APA
陈培芬.,孔英君.,文思.,顾晓雯.,周央.,...&卢洪洲.(2022).噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌肺部感染的病例报道.新发传染病电子杂志,7(2),71-75.
MLA
陈培芬,et al."噬菌体治疗耐碳青霉烯鲍曼不动杆菌合并铜绿假单胞菌肺部感染的病例报道".新发传染病电子杂志 7.2(2022):71-75.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[陈培芬]'s Articles
[孔英君]'s Articles
[文思]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[陈培芬]'s Articles
[孔英君]'s Articles
[文思]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[陈培芬]'s Articles
[孔英君]'s Articles
[文思]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.